Markets
← Back to Stocks
GILD
GILEAD SCIENCES INC
Health Care · Biotechnology
$141.06
-0.17%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Arcellx acquisition bolsters pipeline but stock slides 0.99% in pre-market on earnings concerns
Gilead Sciences declined 0.99% in pre-market to $150.18, with after-hours price at $147.30. Recent analyst upgrades and acquisition of Arcellx bolster growth prospects, and FDA approval of HIV prevention drug Yeztugo adds to positive catalysts. However, Gilead is set to report Q4 earnings with analysts expecting EPS of $1.86, representing a 2.1% decline year-over-year.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$175.2B
P/E (TTM)20.8
Forward P/E14.7
Beta0.37
Div Yield232.00%
Prev Close$141.29
RSI (14-Day)
33Neutral
0305070100
52-Week Range
$93.37$141.06$157.29
From High-10.3%
From Low+51.1%
Moving Averages
50d SMA
$140.94+0.1%
200d SMA
$121.39+16.2%
Price above both MAs — bullish structure.
Returns
1W
-2.3%
1M
-7.1%
3M
+19.4%
6M
+27.2%
1Y
+31.4%
YTD
+16.7%
Volume
Today45K
20d Avg6.4M
Ratio0.01x